<DOC>
	<DOCNO>NCT01076764</DOCNO>
	<brief_summary>Primary Objective : - To demonstrate superior efficacy ( composite all-cause death + Myocardial Infarction ( MI ) ) Otamixaban Unfractionated Heparin ( UFH ) + Eptifibatide Secondary Objectives : - To demonstrate superior efficacy ( composite all-cause death + MI + stroke ) Otamixaban compare UFH + Eptifibatide - To document effect Otamixaban rehospitalization prolongation hospitalization due new episode myocardial ischemia/myocardial infarction compare UFH + eptifibatide - To document effect mortality ( cause death ) Otamixaban compare UFH + eptifibatide - To document safety Otamixaban compare UFH + eptifibatide - To document effect Otamixaban thrombotic procedural complication index Percutaneous Coronary Intervention ( PCI ) compare UFH + eptifibatide</brief_summary>
	<brief_title>Effect Otamixaban Versus Unfractionated Heparin + Eptifibatide Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy</brief_title>
	<detailed_description>Up interim analysis , patient randomize one Otamixaban arm control arm ( UFH + Eptifibatide ) . Then interim analysis , patient randomize continued Otamixaban arm ( per Data Monitoring Committee ( DMC ) decision base interim analysis result ) control arm ( UFH + Eptifibatide ) . Except DMC , participant remain blinded decision end study . The total duration study period per subject range 30 day 180 day . Study end date Day 30 visit last randomized patient , follow Day 180 study end date whichever come first .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Angina , Unstable</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Otamixaban</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Eptifibatide</mesh_term>
	<criteria>Inclusion criterion : Patient nonSTsegment elevation Acute Coronary Syndrome ( NSTEACS ) : 1 . Ischemic symptom ( chest pain equivalent ) rest ≥ 10 minute within 24 hour randomization , AND 2 . One two follow criterion : New STsegment depression ≥ 0.1 mV ( ≥1 mm ) , transient ( &lt; 30 minute ) STsegment elevation ≥ 0.1 mV ( ≥ 1 mm ) least 2 contiguous lead electrocardiogram , Elevation cardiac biomarkers within 24 hour randomization , define elevate troponin T , troponin I , CKMB level upper limit normal , AND 3 . Planned coronary angiography ( follow , indicate , PCI ) early possible ( least 2 hour treatment study drug ) within 36 hour ( late Day 3 , justify ) , AND 4 . Informed consent obtain write . Exclusion criterion : Revascularization procedure already perform qualify event Acute STsegment elevation MI . Patient receive curative dose anticoagulant treatment ( include UFH , LMWH , bivalirudin ) 24 hour prior randomization treat abciximab . Inability discontinue current anticoagulation order transition Investigational Products accord specify transition timing . Patient treat aspirin clopidogrel ( oral antiplatelet agent ) accord local labeling . Patient treat eptifibatide accord national labeling ( available ) . In country eptifibatide approve reference label consider either European labeling US label Patient treat unfractionated heparin accord national labeling . Allergy otamixaban . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>